View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Belgium STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to...

 PRESS RELEASE

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 C...

Greenwich LifeSciences Announces Addition of Portugal to Flamingo-01 Clinical Trial STAFFORD, Texas, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Portugal. The Company's application to European regulators has been formally approved, adding Portugal as an approved country in FLAMINGO-01 in addition...

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Now Arriving: September '25 Online Travel Trends

Key Findings:US hotel RevPAR growth averaged -1% Y/Y QTD through August, decelerating ~60bps from 2Q. RevPAR growth has been slightly negative the last three months after flat growth in May and April. Through the first two weeks of September, US hotel RevPAR has continued to stabilize.International

Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt
Chase Tohanczyn ... (+3)
  • Chase Tohanczyn
  • Matthew Weiss
  • Scott Devitt

Counting Clicks: August '25 Traffic Trends

Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr

 PRESS RELEASE

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...

Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: September 13, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights.com Daily Ratings Report: September 11, 2025

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

BRT Apartments Corp: 1 director

A director at BRT Apartments Corp bought 31,600 shares at 15.958USD and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...

 PRESS RELEASE

BRT Apartments Corp. Declares Third Quarter 2025 Dividend and Announce...

BRT Apartments Corp. Declares Third Quarter 2025 Dividend and Announces Management Appointments GREAT NECK, New York, Sept. 11, 2025 (GLOBE NEWSWIRE) -- BRT APARTMENTS CORP. (NYSE: BRT) announced today that its Board of Directors declared a quarterly dividend of $0.25 per share. The dividend is payable October 6, 2025, to stockholders of record at the close of business on September 24, 2025. Additionally, the Company announces the appointment of Matthew Gibbons and Isaac Kalish as chief accounting officer and chief financial officer, respectively. Mr. Gibbons' appointment is effective im...

 PRESS RELEASE

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation

Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...

Matthew Weiss ... (+2)
  • Matthew Weiss
  • Scott Devitt

Now Arriving: August '25 Online Travel Trends

Key Findings:US hotel RevPAR growth averaged -1.4% Y/Y in July, decelerating ~100bps from 2Q. RevPAR growth has been slightly negative the last two months after flat growth in May and April. Through the first three weeks of August, US hotel RevPAR growth has stabilized, averaging -1% Y/Y.Internatio

Matthew Weiss ... (+2)
  • Matthew Weiss
  • Scott Devitt

Counting Clicks: July '25 Traffic Trends

Report Overview: Our analysis includes total web visits (desktop and mobile) to U.S. and international web domains, mobile app monthly active users (MAUs), daily active users (DAUs), and total time spent (where applicable). Throughout the report, we display Y/Y changes across each of these key metr

 PRESS RELEASE

Noble Capital Markets Initiates Equity Research Coverage on Greenwich ...

Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...

 PRESS RELEASE

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical O...

Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch